Aro Biotherapeutics to Present Corporate Overview at BioCentury Future Leader’s In the Biotech Industry Conference
Philadelphia, PA, April 12, 2019 --- Aro Biotherapeutics, a biotechnology company focused on the research and development of Centyrins to transform the treatment of cancer and other serious diseases, announced Sue Dillon, PhD, CEO and Co-founder will present a corporate overview at the BioCentury Future Leader’s In The Biotech Industry Conference being held at the Millenium Hotel in New York City on April 12, 2019 at 10:00 am ET. Dr. Dillon will also participate in a panel discussion, entitled “Why VCs & Pharma Entrepreneurs Are Building Hot Topic Companies,” at 11:00 am.
“Over the course of our first year, Aro developed from a virtual company to a fully operational executive and scientific team with established capabilities in protein engineering, chemistry, and the biology of cancer and immune diseases, complemented by an expert team of consultants in manufacturing and development,” said Dr. Dillon. “We are excited about the progress of both of our oncology programs, which leverage the unique properties of our Centyrins proteins.”
Building a Pipeline of Life Changing Therapies
Centyrins are small, structurally simple, ultra-stable, highly soluble proteins. These characteristics enable the discovery of medicines with new mechanisms of action for cancer and other devastating diseases. Aro’s lead program, which is a bi-specific Centyrin, is in late-stage lead optimization for advanced non-small cell lung cancer. Aro’s second therapeutic program is focused on creating a Centyrin-siRNA conjugate for other forms of cancer. This first-of-its-kind combination is designed to address unmet medical needs by targeting drug payloads in high concentration to the site of disease, while lowering the toxicity to non-target organs. The company holds an exclusive worldwide license for research, development, manufacturing and commercialization of Centyrin protein therapeutics.
About Aro Biotherapeutics
Aro is a biotechnology company focused on the research and development of a new generation of protein biologics called Centyrins. The company is developing a wholly-owned pipeline of Centyrins for oncology and immunology, and is working with leaders in the industry on leveraging Centyrins for delivery of a variety of drug payloads, including nucleic acid drugs for a diverse set of diseases. For more information, visit www.arobiotx.com.
Sam Brown Inc.